Prof. Winnie Yeo






Name


Winnie Yeo

Chinese Name


杨明明

Qualifications


MBBS AKC MD FRCP (Lon) FRCP (Edin) FHKAM FHKCP

Rank


Professor

Email


winnieyeo@cuhk.edu.hk

Specific Research / Sites of Interest


Breast cancer

Gastric cancer

Hepatocellular carcinoma

Hepatitis B virus-related complications in cancer patients

Survivorship studies


Short Biography


Professor Winnie Yeo graduated from King’s College Hospital, University of London. She underwent postgraduate training in Addenbrooke’s Hospital, Cambridge, and at King’s College, Westminster and Royal Marsden Hospitals in London before returning to Hong Kong. Professor Yeo was the Chairman of the Medical Oncology Specialty of the Hong Kong College of Physicians between 2007 and 2013. She is an Honorary Consultant in the Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong and a Co-director of the Comprehensive Cancer Trials Unit of the Department of Clinical Oncology, Faculty of Medicine, the Chinese University of Hong Kong. She serves as a member and advisor in various expert panels and committees within the University, the Hong Kong Hospital Authority and various health advisory panels. She has authored and coauthored over 230 papers including leading authorships for publications in journals including Journal of the National Cancer Institute, Journal of Clinical Oncology, Hepatology, Annals of Oncology etc. Her main research interests are management of breast, liver and gastric cancer patients as well as hepatitis B virus-related complications in cancer patients.

Most Representative Publications


W Yeo, PKS Chan, WM Ho, B Zee, KC Lam, KIK Lei, ATC Chan, TSK Mok, JJ Lee, TWT. Leung, S Zhong, PJ Johnson. Lamivudine for the Prevention of Hepatitis B virus Reactivation in HBsAg Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy. J Clin Oncol 2004, 22(5): 927-934.

W Yeo, TS Mok, B Zee, WT Leung, PBS Lau, WY Lau, J Koh, MKF Mo, S Yu, A T Chan, P Hui, B Ma, KC Lam, WM Ho, HT Wong, PJ Johnson. Phase III study of adriamycin versus cisplatin/interferon a-2b/adriamycin/ fluorouracil combination chemotherapy for inoperable hepatocellular carcinoma. J Natl Cancer Inst 2005, 97(20): 1532-1538.

W Yeo, PJ Johnson. Diagnosis, prevention and management of hepatitis B virus reactivation during anti-cancer therapy. Hepatology 2006, 43(2): 209-221.

W Yeo, FKF Mo, J Koh, ATC Chan, T Leung, P Hui, L Chan, A Tang, JJ Lee, TSK Mok, PBS Lai, PJ Johnson, B Zee. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Annals of Oncology 2006, 17; 1083-1089.

W Yeo, FKF Mo, SL Chan, NWY Leung, P Hui, WY Lam, TSK Mok, KC Lam, WM Ho, J Koh, JW Tang, AT Chan, PKS Chanl. Hepatitis B Viral Load Predicts Survival of Patients with Hepatocellular Carcinoma (HCC) Undergoing Systemic Chemotherapy. Hepatology 2007, 45: 1382-1389.

W Yeo, TC Chan, NWY Leung, TC Chan, NWY Leung, WY Lam, F Mo, MT Chu, HLY Chan, EP Hui, KIK Lei, T Mok, PKS Chan. Hepatitis B Virus Reactivation in Lymphoma Patients with History of resolved Hepatitis B Being Treated with or without Rituximab-containing Anti-cancer Therapy. J Clin Oncol 2009, 27(4): 605-611.

Yeo W, Mo FK, Suen JJ, WM Ho, SL Chan, W Lau, J Koh, WK Yeung, WH Kwan, KKC Lee, TSK Mok, ANY Poon, KC Lam, EK Hui, B Zee. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat 2009;113(3):529-35.

W Yeo, PJ Chen, J Furuse, KH Han, C Hsu, H-Y Lim, H Moon, S Qin, EM Yeoh, SL Ye. Eastern Asian Expert Panel Opinion: Designing Clinical Trials of Molecular Targeted Therapy for Hepatocellular Carcinoma. BMC Cancer 2010, 10:620.

W Yeo, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FK, Koh J, Rha SY, Hui EP, Jeung HC, Roh JK, Yu SC, To KF, Tao Q, Ma BB, Chan AW, Tong JH, Erlichman C, Chan AT, Goh BC. Epigenetic Therapy Using Belinostat for Patients with Unresectable Hepatocellular Carcinoma. Carcinoma: A multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol 2012, 30(27): 3361-67.

Yeo W, Chan SL, Mo FKF, et al. Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. BMC Cancer 2015; 15:395. DOI 10.1186/s12885-015-1334-6.